University of Hertfordshire

From the same journal

Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy

Research output: Contribution to journalArticlepeer-review

Standard

Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy. / Okwuosa, Tochukwu C; Pereira, Beatriz C; Arafat, Basel; Cieszynska, Milena; Isreb, Abdullah; Alhnan, Mohamed A.

In: Pharmaceutical Research, Vol. 34, No. 2, 02.2017, p. 427-437.

Research output: Contribution to journalArticlepeer-review

Harvard

Okwuosa, TC, Pereira, BC, Arafat, B, Cieszynska, M, Isreb, A & Alhnan, MA 2017, 'Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy', Pharmaceutical Research, vol. 34, no. 2, pp. 427-437. https://doi.org/10.1007/s11095-016-2073-3

APA

Okwuosa, T. C., Pereira, B. C., Arafat, B., Cieszynska, M., Isreb, A., & Alhnan, M. A. (2017). Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy. Pharmaceutical Research, 34(2), 427-437. https://doi.org/10.1007/s11095-016-2073-3

Vancouver

Author

Okwuosa, Tochukwu C ; Pereira, Beatriz C ; Arafat, Basel ; Cieszynska, Milena ; Isreb, Abdullah ; Alhnan, Mohamed A. / Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy. In: Pharmaceutical Research. 2017 ; Vol. 34, No. 2. pp. 427-437.

Bibtex

@article{d3c6b70541f040ffaee5b4f62a739e74,
title = "Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy",
abstract = "PURPOSE: Individualizing gastric-resistant tablets is associated with major challenges for clinical staff in hospitals and healthcare centres. This work aims to fabricate gastric-resistant 3D printed tablets using dual FDM 3D printing.METHODS: The gastric-resistant tablets were engineered by employing a range of shell-core designs using polyvinylpyrrolidone (PVP) and methacrylic acid co-polymer for core and shell structures respectively. Filaments for both core and shell were compounded using a twin-screw hot-melt extruder (HME). CAD software was utilized to design a capsule-shaped core with a complementary shell of increasing thicknesses (0.17, 0.35, 0.52, 0.70 or 0.87 mm). The physical form of the drug and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC.RESULTS: A shell thickness ≥0.52 mm was deemed necessary in order to achieve sufficient core protection in the acid medium. The technology proved viable for incorporating different drug candidates; theophylline, budesonide and diclofenac sodium. XRPD indicated the presence of theophylline crystals whilst budesonide and diclofenac sodium remained amorphous in the PVP matrix of the filaments and 3D printed tablets. Fabricated tablets demonstrated gastric resistant properties and a pH responsive drug release pattern in both phosphate and bicarbonate buffers.CONCLUSIONS: Despite its relatively limited resolution, FDM 3D printing proved to be a suitable platform for a single-process fabrication of delayed release tablets. This work reveals the potential of dual FDM 3D printing as a unique platform for personalising delayed release tablets to suit an individual patient's needs.",
keywords = "Budesonide/chemistry, Capsules/chemistry, Delayed-Action Preparations/chemistry, Diclofenac/chemistry, Drug Compounding/methods, Drug Liberation, Hot Temperature, Humans, Patient-Centered Care, Polymers/chemistry, Povidone/chemistry, Printing, Three-Dimensional, Tablets/chemistry, Theophylline/chemistry",
author = "Okwuosa, {Tochukwu C} and Pereira, {Beatriz C} and Basel Arafat and Milena Cieszynska and Abdullah Isreb and Alhnan, {Mohamed A}",
year = "2017",
month = feb,
doi = "10.1007/s11095-016-2073-3",
language = "English",
volume = "34",
pages = "427--437",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Fabricating a Shell-Core Delayed Release Tablet Using Dual FDM 3D Printing for Patient-Centred Therapy

AU - Okwuosa, Tochukwu C

AU - Pereira, Beatriz C

AU - Arafat, Basel

AU - Cieszynska, Milena

AU - Isreb, Abdullah

AU - Alhnan, Mohamed A

PY - 2017/2

Y1 - 2017/2

N2 - PURPOSE: Individualizing gastric-resistant tablets is associated with major challenges for clinical staff in hospitals and healthcare centres. This work aims to fabricate gastric-resistant 3D printed tablets using dual FDM 3D printing.METHODS: The gastric-resistant tablets were engineered by employing a range of shell-core designs using polyvinylpyrrolidone (PVP) and methacrylic acid co-polymer for core and shell structures respectively. Filaments for both core and shell were compounded using a twin-screw hot-melt extruder (HME). CAD software was utilized to design a capsule-shaped core with a complementary shell of increasing thicknesses (0.17, 0.35, 0.52, 0.70 or 0.87 mm). The physical form of the drug and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC.RESULTS: A shell thickness ≥0.52 mm was deemed necessary in order to achieve sufficient core protection in the acid medium. The technology proved viable for incorporating different drug candidates; theophylline, budesonide and diclofenac sodium. XRPD indicated the presence of theophylline crystals whilst budesonide and diclofenac sodium remained amorphous in the PVP matrix of the filaments and 3D printed tablets. Fabricated tablets demonstrated gastric resistant properties and a pH responsive drug release pattern in both phosphate and bicarbonate buffers.CONCLUSIONS: Despite its relatively limited resolution, FDM 3D printing proved to be a suitable platform for a single-process fabrication of delayed release tablets. This work reveals the potential of dual FDM 3D printing as a unique platform for personalising delayed release tablets to suit an individual patient's needs.

AB - PURPOSE: Individualizing gastric-resistant tablets is associated with major challenges for clinical staff in hospitals and healthcare centres. This work aims to fabricate gastric-resistant 3D printed tablets using dual FDM 3D printing.METHODS: The gastric-resistant tablets were engineered by employing a range of shell-core designs using polyvinylpyrrolidone (PVP) and methacrylic acid co-polymer for core and shell structures respectively. Filaments for both core and shell were compounded using a twin-screw hot-melt extruder (HME). CAD software was utilized to design a capsule-shaped core with a complementary shell of increasing thicknesses (0.17, 0.35, 0.52, 0.70 or 0.87 mm). The physical form of the drug and its integrity following an FDM 3D printing were assessed using x-ray powder diffractometry (XRPD), thermal analysis and HPLC.RESULTS: A shell thickness ≥0.52 mm was deemed necessary in order to achieve sufficient core protection in the acid medium. The technology proved viable for incorporating different drug candidates; theophylline, budesonide and diclofenac sodium. XRPD indicated the presence of theophylline crystals whilst budesonide and diclofenac sodium remained amorphous in the PVP matrix of the filaments and 3D printed tablets. Fabricated tablets demonstrated gastric resistant properties and a pH responsive drug release pattern in both phosphate and bicarbonate buffers.CONCLUSIONS: Despite its relatively limited resolution, FDM 3D printing proved to be a suitable platform for a single-process fabrication of delayed release tablets. This work reveals the potential of dual FDM 3D printing as a unique platform for personalising delayed release tablets to suit an individual patient's needs.

KW - Budesonide/chemistry

KW - Capsules/chemistry

KW - Delayed-Action Preparations/chemistry

KW - Diclofenac/chemistry

KW - Drug Compounding/methods

KW - Drug Liberation

KW - Hot Temperature

KW - Humans

KW - Patient-Centered Care

KW - Polymers/chemistry

KW - Povidone/chemistry

KW - Printing, Three-Dimensional

KW - Tablets/chemistry

KW - Theophylline/chemistry

U2 - 10.1007/s11095-016-2073-3

DO - 10.1007/s11095-016-2073-3

M3 - Article

C2 - 27943014

VL - 34

SP - 427

EP - 437

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 2

ER -